40+ results for "financial"
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms a
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
PRESS RELEASE AB SCIENCE REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026 AND KEY EVENTS OF THE PERIOD Change in AB Science's governance and implementation of a new strategy Appointment of Stéphane Ledermann as Chairman and Chief Executive Officer In-depth overhaul of the Company's organisation and strategy Priority given to the development of a new quality assurance system Web conference to be held on Wednesday 14 October 2026 at 6:00 pm to present the Company's new ambitions in detail
Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026
MONTVALE, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Third quarter results will be published prior to the market opening on Friday, October 23, 2026. The press release, and its accompanying financial exhibits, will also be
NTG Nordic Transport Group A/S - Q3 2026 Conference Call
NTG Nordic Transport Group A/S – Q3 2026 Conference Call We expect to release the Q3 2026 interim results of NTG Nordic Transport Group on the evening of November 9, 2026. A webcast and conference call will be held on the morning of November 10, 2026, at 10:00 am CET. At the call, Group CEO Mathias Jensen-Vinstrup and Group CFO Tinneke Torpe will present the Q3 2026 Interim Financial Report. The presentation will be followed by a Q&A session. Date: November 10, 2026 Time: 10:00 am CET To attend
Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 third quarter earnings conference call on Thursday, November 5, 2026, at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/e
Banks Think They're Ready for Tomorrow's Fraud. Feedzai's Survey Suggests Otherwise
Feedzai s new Fraud Readiness Index finds financial institutions are spending heavily on AI, but disconnected data and manual work are holding fraud teams back. NEW YORK and LISBON, Portugal , Oct. 8, 2026 -- Banks and fintechs are confident they re ready for the next wave of fraud, but the evidence suggests they re overestimating themselves. In Feedzai s latest research report, Confidence & Capability: The Feedzai Fraud Readiness Index 2026 which surveyed more than 1,000 senior fraud leaders across 12 countries financial institutions rated their own fraud readiness at an average score of 80.2 out of 100. But when measured against their actual capabilities across data, AI, intelligence sharing, and fraud team operations, the average dropped to 66.9.
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance
Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial guidance for the full year 2026, reflecting stronger-than-expected performance in its Travel Health business. Revenue from Travel Health is now expected to reach approximately DKK 3,400 million, compared to previous guidance of approximately DKK 3,000 million. The increase is prima
Participation notifications by SIH Partners
Press release Regulated information Brussels, October 7, 2026, 17:45 CEST In line with Belgian transparency legislation (Law of May 2, 2007), SIH Partners, LLLP recently sent to Solvay the following transparency notifications indicating that they crossed different thresholds. Here is a summary of the notifications: Date on which the threshold is crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total September 30, 2026 0.19% 4.94% 5.13% October 6,
Virbac : Declaration of the number of shares et voting rights 09/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577 Date Total number of shares representing the share capital Total number of voting rights September, 30 2026 8 390 660 Gross total of voting rights : 12 705 414 Ne
Acquisition of Own Shares
Mechelen, Belgium; October 06, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between September 28, 2026, and October 02, 2026, it has repurchased 117,437 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid
Press Release : Availability of the aide-mémoire for Q3 2026 results
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026 . Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q3 2026 results will be published on October 30, 2026. About Sanofi Sanofi is
Innospec Schedules Third Quarter 2026 Earnings Release and Conference Call
ENGLEWOOD, Colo., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP) today announced that it will release third quarter 2026 earnings results on Tuesday, November 3, 2026 after market close. Following the release of its results, Patrick S. Williams, President and Chief Executive Officer, and Ian Cleminson, Executive Vice President and Chief Financial Officer, will host an interactive conference call on Wednesday, November 4, 2026, at 9:00 a.m. ET. The public is invited to listen to t
Hawkins, Inc. to Release Second Quarter Fiscal 2027 Financial Results on October 26, 2026
ROSEVILLE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN) announced today that it expects to release its financial results for its second quarter fiscal 2027 ended September 27, 2026 after the market closes on October 26, 2026 at approximately 4:10 p.m. Eastern Time. About Hawkins, Inc. Hawkins, Inc. was founded in 1938 and is a leading water treatment and specialty ingredients company that formulates, manufactures, distributes, and blends products for its Water Treatment,
Sofwave to Participate in the Jefferies Private MedTech Virtual Summit
SAN CLEMENTE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Jefferies Private MedTech Virtual Summit on October 7 – 8, 2026. Jefferies Private MedTech Virtual Summit Presentation Format: Corporate overview Presentation Dat
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Sum
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company’s executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in
Participation notification by Citigroup Inc.
Press release Regulated information Brussels, October 1, 2026, 17:45 CEST In line with Belgian transparency legislation (Law of May 2, 2007), Citigroup Inc. recently sent to Solvay the following transparency notification indicating that it crossed the threshold of 3%. Here is a summary of the notification: Date on which the threshold is crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total September 24, 2026 0.43% 2.66% 3.09% The notification, d
5paisa Capital Wins Best Fintech Broker Award, Cements AI-First Vision at Money Expo 2026
MUMBAI, India , Oct. 1, 2026 -- 5paisa Capital , one of India s leading digital-first financial services platforms, participated as a Titanium Sponsor at the recently held Money Expo 2026 and was recognized with the Best Fintech Broker award , reinforcing its position as a trusted, technology-led platform for traders and investors across India. 5paisa Capital has strengthened its position as a trader-focused, AI-first broker through three key moves: the launch of AlgoSpace, a no-code algo trading platform for retail investors; 5paisa MCP, its Claude-powered natural-language trading assistant for research and back-testing; and a strategic partnership with OpenAI to bring personalised AI-driven investing advisory to users, with plans to make its services accessible within ChatGPT.
NuSummit Appoints Kunal Purohit as Managing Director and CEO
MUMBAI, India , Oct. 1, 2026 -- NuSummit , a leading global provider of AI-led cybersecurity, data, digital, and cloud transformation solutions across Capital Markets, Insurance, Banking, and Financial Services, today announced the appointment of Kunal Purohit as Managing Director and CEO . Anantharaman Sreenivasan (Ganesh) , who led NuSummit through five years of growth, integration, and transformation, will transition from his current role as MD and CEO immediately and continue as an Executive Director on NuSummit s Board till 31st March 2027, supporting the leadership transition.
OuterSignal Raises $22 Million in Series A Funding Round: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK , Sept. 30, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today s NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on September 30th OuterSignal says its fresh capital will help it bring agentic personalization to every consumer brand. The agentic customer intelligence platform is focusing on bolstering its research engine and building personalization that generates a version of every message for every customer. Founder Noah Friedman told the NYSE at Uncharted s Fame to Fortune event that commerce has not kept up with the people who supported it. Triumph Financial has released its inaugural Triumph Mile Marker report, highlighting notable industry shifts. The company s research suggests that the trucking industry is entering a new era defined by the availability of capacity that can be deployed with confidence. Triumph s report spotlights trends that may reshape how brokers, carriers, and shippers evaluate market conditions in the coming months. Triumph s Founder, Vice Chair, and CEO Aaron Graft will join NYSE Live to explain how businesses can position themselves for success based off the report s findings. Investors are parsing through a pair of economic reports that dropped earlier today. The August PCE Price Index and the final Q2 GDP reading provide the latest glimpse of the U.S. economy. Traders are reacting to September ADP private payrolls data, offering insight into private sector employment ahead of Friday s September jobs report. The U.S. 30-year Treasury yield hit its highest mark since 2002 as bond yields remain elevated.
IBM Study: As AI Scales Enterprise-Wide, CFOs Play an Expanded Role in Transformation
Most CFOs report their role has expanded into enterprise technology or AI strategy leadership By 2030, more than half of surveyed CFOs expect to help design financial and ethical guardrails for AI ARMONK, N.Y. , Sept. 30, 2026 -- A new global study from the IBM (NYSE: IBM ) Institute for Business Value finds that as AI becomes more integrated into enterprise operations and decision-making, CFOs are taking on a larger role in shaping enterprise priorities around AI, helping turn strategy into execution, and determining how investments and capital allocation support them.
Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026
Ad hoc announcement pursuant to Art. 53 LR. A conference call will be held on September 30, 2026, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Strong momentum and expanding global access position AGAMREE® for continued growth Pratteln, Switzerland, September 30, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the six months ended June 30, 2026. Orlando Oliveira, CEO of Santhera said : “We made strong progress in the
Acquisition of Own Shares
Mechelen, Belgium; 29 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between September 21, 2026, and September 25, 2026, it has repurchased 106,060 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price pa
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027 MELBOURNE, Australia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced an update on corporate progress and reported year-end financial results as of June 30, 2026 (Year end June 30). CORPORATE HIGHLIGHTS To commence
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE INSPECTION Confirmation of the relevance of having, among the first decisions of the new management, given priority to the development of a new quality management system Expected resumption of the AB8939 phase 1 (acute myeloid leukemia) in the first quarter of 2027, followed by the masitinib phase 3 (amyotrophic lateral sclerosis) in the last quarter of 2027, subj
GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
Financial Highlights Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028 €21.1 million in revenues as of June 30, 2026, including €21.0 million in royalties generated under the Ipsen agreement Key Highlights PBC: Ipsen doubled its peak annual global sales target for Iqirvo® in PBC to €1 billion, underscoring the value creation potential of GENFIT's licensing agreement MASH: Medicare coverage secured in August 2026 in the Unite
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026
Aggregated presentation by day and by market Weekly report on share repurchases from 21st September to 22nd September 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) IPSEN 549300M6SGDPB4Z94P11 21/09/2026 FR0010259150 21 158 146,4614 XPAR IPSEN 549300M6SGDPB4Z94P11 21/09/2026 FR0010259150 7 870 146,0726 CEUX IPSEN 549300M6SGDP
Guerbet : H1 2026 Results.
H1 2026 Results Revenue of €379.2m, nearly stable (-0.1%) at CER 1 and like-for-like 2 , in line with the Group’s forecast for the full year EBITDA of €30.6m, in line with the Group’s forecast for the full year Restated EBITDA margin 3 of 9.1%, versus 12.9% a year earlier, including €14.3m in exceptional costs related to the remediation plan at the Raleigh site Financial leverage of 5.3x; ongoing discussions with financial partners to agree a refinancing arrangement by October 31, 2026 Raleigh i
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 1 as of June 30, 2026 Cash runway guidance remains unchanged from July 30, 2026 2 Topline results of the Phase 3 NATiV3 clinical trial are expected in the fourth quarter of 2026 Key highlights from the first half of 2026 and recent Company updates Management to host webcast today at 8:00 AM ET to discuss first-half 2026 financial results Daix (France), New York (New York, United States), September 28, 2026 – Inv
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
€11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026 The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash runway beyond key upcoming value inflection points In this context, publication of first half 2026 financial results is postponed Enrolment of Tedopi’s Phase 3 clinical trial ARTEMIA in lung cancer on track for completion by end of December 2026; planned futility analysis now estimated
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update. “The successful raising of USD 2.8 million during the last quarter enables us to continue advancing our in-house GABA
5paisa Brings AI-First Trading to the World Stage at Global Fintech Fest 2026
MUMBAI, India , Sept. 28, 2026 -- 5paisa Capital, one of India s leading digital-first financial services platforms, participated as a Silver Sponsor at the Global Fintech Fest 2026, held from September 8-11, reinforcing its commitment to building trusted, technology-led financial solutions for investors and traders across India. 5paisa Capital has strengthened its position as a trader-focused, AI-first broker through three key moves: the launch of AlgoSpace, a no-code algo trading platform for retail investors; 5paisa MCP, its Claude-powered natural-language trading assistant for research and back testing; and a strategic partnership with OpenAI to bring personalised AI-driven investing advisory to users, with plans to make its services accessible within ChatGPT.
Participation notification by Citigroup Inc.
Press release - Regulated information Brussels, September 25, 2026, 17:45 CEST In line with Belgian transparency legislation (Law of May 2, 2007), Citigroup Inc. recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%. Here is a summary of the notification: Date on which the threshold is crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total September 21, 2026 - - - The notification, dated
Tilray Brands to Announce First Quarter Fiscal Year 2027 Financial Results on October 8, 2026
NEW YORK and LONDON and LEAMINGTON, Ontario, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc . (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, hospitality and wellness industries, today announced that the Company will release its financial results for the first fiscal quarter ended August 31, 2026, before the financial markets open on Thursday, October 8, 2026. Live Conference Call and
Comviva Appoints Jeet Singh to Drive Global Growth, Transformation and Strategic Partnerships
NEW DELHI , Sept. 25, 2026 -- Comviva , a global leader in digital transformation solutions, specializing in customer experience management, data monetization, and digital financial services, today announced the appointment of Jeet Singh as Global Head Strategy, Transformation and Alliances. Jeet will spearhead Comviva s strategic priorities for its next phase of growth, with a focus on expanding its presence across developed markets, entering new industry verticals, and identifying new avenues for sustainable growth. He will also drive the company s global alliances strategy, strengthening strategic partnerships and ecosystems to accelerate market expansion and create new opportunities for Comviva.
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation Strengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029 Acceptable safety profile and promising initial efficacy responses o
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s web
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026. Tumor HI upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumo
Participation notification by SIH Partners
Press release Regulated information Brussels, September 24, 2026, 17:45 CEST In line with Belgian transparency legislation (Law of May 2, 2007), SIH Partners, LLLP recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%. Here is a summary of the notification: Date on which the threshold is crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total September 18, 2026 - - - The notification, date
Hyperion DeFi Supports DoubleZero Edge in Launching the Fastest Commercially Available Hyperliquid Data Feeds
DALLAS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced its first initiative to bring an infrastructure team from another blockchain into the Hyperliquid ecosystem. Under the Company’s agreement with DoubleZero Edge, Hyperion DeFi will support DoubleZero in launching the fastest commercially available Hyperliquid data feeds. “DoubleZero Edge was designed to be the market-data transport layer for financial venues, and with